Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03265171
Expanded Access Status : No longer available
First Posted : August 29, 2017
Last Update Posted : April 24, 2020
Cedars-Sinai Medical Center
Vanderbilt University Medical Center
Indiana Hemophilia &Thrombosis Center, Inc.
Information provided by (Responsible Party):
Prometic Biotherapeutics, Inc.

Brief Summary:
These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

Condition or disease Intervention/treatment
Hypoplasminogenemia Biological: Plasminogen (Human)

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patient has provided informed consent.
  • Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.

Exclusion Criteria:

  • Not applicable

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Prometic Biotherapeutics, Inc. Identifier: NCT03265171    
Other Study ID Numbers: 2002C013G
First Posted: August 29, 2017    Key Record Dates
Last Update Posted: April 24, 2020
Last Verified: April 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action